Bevacizumab

Term: BevacizumabDefinition: Bevacizumab is a monoclonal antibody used in the treatment of various cancers, including those potentially linked to asbestos exposure, by inhibiting the growth of new blood vessels that tumors need to grow.Phonetic Pronunciation: (bev-a-SIZ-oo-mab)Origin: The name "Bevacizumab" is derived from biotechnology nomenclature. "Beva-" refers to the company that developed it, Genentech, while "-cizu-" indicates it is a humanized monoclonal antibody, and "-mab" is the suffix for monoclonal antibodies. This naming convention helps in identifying the drug's type and origin in the scientific community.Significance in Asbestos Context: Bevacizumab's significance in asbestos-related issues stems from its potential use in treating malignant mesothelioma, a cancer strongly associated with asbestos exposure. It offers a targeted therapy option that can be part of a comprehensive treatment plan for affected individuals, potentially improving outcomes and quality of life.Example Sentence: "The oncologist recommended bevacizumab as part of a combination therapy to manage the patient's asbestos-related lung cancer."Related Terms: Monoclonal antibody, angiogenesis inhibitor, malignant mesothelioma, targeted therapy, cancer treatment.Notes: - Bevacizumab is often used in combination with other chemotherapy drugs. - While promising, its use in asbestos-related diseases is still under investigation and may not be universally covered by insurance. - Side effects can include hypertension and bleeding, which require careful monitoring.